Gilteritinib

Red

Brand Name(s):

Indication:Treatment of relapsed or refractory FLT3?mutation +ve AML in adults

Rationale:1,2,8

Considered:Oct-20

Review Date:Oct-25

Comments:
NICE TA642 – Gilteritinib monotherapy is recommended as an option for treating relapsed or refractory FLT3 mutation +ve AML in adults. It should not be given as maintenance therapy after a haematopoietic stem cell transplant.